Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience

Abstract We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean chang...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Matteo Fallico, Andrea Maugeri, Andrew Lotery, Antonio Longo, Vincenza Bonfiglio, Andrea Russo, Teresio Avitabile, Claudio Furino, Gilda Cennamo, Martina Barchitta, Antonella Agodi, Paola Marolo, Luca Ventre, Paolo Caselgrandi, Michele Reibaldi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6e4a5ce518fe424c879b866e62d312c0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e4a5ce518fe424c879b866e62d312c0
record_format	dspace
spelling	oai:doaj.org-article:6e4a5ce518fe424c879b866e62d312c02021-12-02T15:53:03ZFluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience10.1038/s41598-021-84362-y2045-2322https://doaj.org/article/6e4a5ce518fe424c879b866e62d312c02021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84362-yhttps://doaj.org/toc/2045-2322Abstract We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included. The FAc implant yielded a significantly improved BCVA at 24 and 36 months (24-month MD = 4.52; 95% CI 2.56–6.48; 36-month MD = 8.10; 95% CI 6.34–9.86). These findings were comparable with the FAME study. The FAc implant yielded significantly reduced 24- and 36-month CMT. Pooled proportions of cataract surgery, IOP-lowering drops and glaucoma surgery were 39%, 27% and 3%, respectively, all lower than the FAME study. Pooled estimate of supplementary intravitreal therapy was 39%, higher than the 15.2% of the FAME study. This meta-analysis of real-world studies confirms favorable visual and anatomical outcomes following FAc insert for chronic DMO. In real-life studies more than one third of patients received supplementary intravitreal therapy, an issue that needs to be further explored.Matteo FallicoAndrea MaugeriAndrew LoteryAntonio LongoVincenza BonfiglioAndrea RussoTeresio AvitabileClaudio FurinoGilda CennamoMartina BarchittaAntonella AgodiPaola MaroloLuca VentrePaolo CaselgrandiMichele ReibaldiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Matteo Fallico Andrea Maugeri Andrew Lotery Antonio Longo Vincenza Bonfiglio Andrea Russo Teresio Avitabile Claudio Furino Gilda Cennamo Martina Barchitta Antonella Agodi Paola Marolo Luca Ventre Paolo Caselgrandi Michele Reibaldi Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
description	Abstract We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included. The FAc implant yielded a significantly improved BCVA at 24 and 36 months (24-month MD = 4.52; 95% CI 2.56–6.48; 36-month MD = 8.10; 95% CI 6.34–9.86). These findings were comparable with the FAME study. The FAc implant yielded significantly reduced 24- and 36-month CMT. Pooled proportions of cataract surgery, IOP-lowering drops and glaucoma surgery were 39%, 27% and 3%, respectively, all lower than the FAME study. Pooled estimate of supplementary intravitreal therapy was 39%, higher than the 15.2% of the FAME study. This meta-analysis of real-world studies confirms favorable visual and anatomical outcomes following FAc insert for chronic DMO. In real-life studies more than one third of patients received supplementary intravitreal therapy, an issue that needs to be further explored.
format	article
author	Matteo Fallico Andrea Maugeri Andrew Lotery Antonio Longo Vincenza Bonfiglio Andrea Russo Teresio Avitabile Claudio Furino Gilda Cennamo Martina Barchitta Antonella Agodi Paola Marolo Luca Ventre Paolo Caselgrandi Michele Reibaldi
author_facet	Matteo Fallico Andrea Maugeri Andrew Lotery Antonio Longo Vincenza Bonfiglio Andrea Russo Teresio Avitabile Claudio Furino Gilda Cennamo Martina Barchitta Antonella Agodi Paola Marolo Luca Ventre Paolo Caselgrandi Michele Reibaldi
author_sort	Matteo Fallico
title	Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
title_short	Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
title_full	Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
title_fullStr	Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
title_full_unstemmed	Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
title_sort	fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6e4a5ce518fe424c879b866e62d312c0
work_keys_str_mv	AT matteofallico fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT andreamaugeri fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT andrewlotery fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT antoniolongo fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT vincenzabonfiglio fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT andrearusso fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT teresioavitabile fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT claudiofurino fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT gildacennamo fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT martinabarchitta fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT antonellaagodi fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT paolamarolo fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT lucaventre fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT paolocaselgrandi fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience AT michelereibaldi fluocinoloneacetonidevitreousinsertforchronicdiabeticmacularoedemaasystematicreviewwithmetaanalysisofrealworldexperience
_version_	1718385515010457600

Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience

Ejemplares similares